Case-Based Roundtable
General Dermatology
Eczema
Chronic Hand Eczema
Alopecia
Aesthetics
Vitiligo
COVID-19
Actinic Keratosis
Precision Medicine and Biologics
Rare Disease
Wound Care
Rosacea
Psoriasis
Psoriatic Arthritis
Atopic Dermatitis
Melasma
NP and PA
Skin Cancer
Hidradenitis Suppurativa
Drug Watch
Pigmentary Disorders
Acne
Pediatric Dermatology
Practice Management
Prurigo Nodularis
Buy-and-Bill

Assessing the Use of JAK Inhibitors in Atopic Dermatitis Management : Episode 11

Opinion

Video

April 4, 2025

Overcoming Therapeutic Inertia in a 25-Year-Old Man with Moderate to Severe Atopic Dermatitis

Author(s):

Lisa Swanson, MD, FAAD,Linda Stein Gold, MD

Panelists discuss how clinicians can recognize and address barriers to treatment advancement in a young adult with persistent moderate to severe atopic dermatitis by evaluating disease impact, patient concerns, and appropriate therapeutic options.

EP: 1.Determining Atopic Dermatitis Severity and When to Advance to Systemic Therapy

EP: 2.Optimizing Disease Control and AAD Guidelines for Systemic Therapies

EP: 3.Selecting Systemic Therapy for Patients with Moderate to Severe Atopic Dermatitis

EP: 4.The JAK-STAT Signaling Pathway and Its Role in Atopic Dermatitis

EP: 5.The Impact of JAK Selectivity in Atopic Dermatitis Treatment

EP: 6.Efficacy, Safety, and Role in Therapy of JAK Inhibitors for Atopic Dermatitis

EP: 7.Navigating the Boxed Warning for the JAK Inhibitor Class

EP: 8.Talking to Patients About the Safety of JAK Inhibitors in Atopic Dermatitis

EP: 9.Laboratory Monitoring with Oral JAK Inhibitors

EP: 10.Differentiating Between JAK Inhibitors in Clinical Practice

Now Viewing

EP: 11.Overcoming Therapeutic Inertia in a 25-Year-Old Man with Moderate to Severe Atopic Dermatitis

EP: 12.Switching from Biologics to JAK Inhibitors in Nonresponders and Dose Escalation

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Subscribe Now!